ArticleOncogene2026
TIAL1 regulates the Hippo pathway through an RNA-binding-independent mechanism.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
The Hippo pathway is an evolutionarily conserved signaling cascade whose dysregulation is implicated in a wide range of diseases. While many RNA-binding proteins (RBPs) regulate this pathway through canonical functions such as modulating mRNA stability and translation, the potential for RBP-mediated regulation via non-canonical, RNA-binding-independent mechanisms remains poorly defined. Here, we report that the RBP TIAL1 exhibits oncogenic properties in hepatocellular carcinoma, promoting cancer cell proliferation, migration, and invasion. Mechanistically, TIAL1 directly interacts with the core Hippo component SAV1, disrupting the MST1-SAV1 interaction and thereby suppressing Hippo signaling and activating YAP. Notably, this regulatory function is independent of the RNA-binding activity of TIAL1. Furthermore, extracellular stimuli such as energy surplus and EGF significantly upregulate TIAL1 expression, linking microenvironmental cues to Hippo pathway dysregulation. Together, our results reveal a previously unrecognized, RNA-binding-independent mode of RBP-mediated regulation, in which TIAL1 serves as a molecular integrator that conveys extracellular signals to the Hippo pathway to drive hepatocellular carcinoma progression, providing potential avenues for therapeutic intervention.
Indexed as
Identifiers
42032365What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.